The present invention is directed to compounds of formula (I), wherein R<SUP>1</SUP> is a ring, R<SUP>5</SUP> is a specified substituent, and n is from 1 to 8. The invention also relates to the use of the compounds in therapy as metabotropic glutamate receptors modulators, particularly in neurological and psychiatric disorders.
